DelveInsight’s ‘Intrahepatic Cholangiocarcinoma Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline Intrahepatic Cholangiocarcinoma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Intrahepatic Cholangiocarcinoma pipeline domain.
For Intrahepatic Cholangiocarcinoma emerging drugs, the Intrahepatic Cholangiocarcinoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Intrahepatic Cholangiocarcinoma Pipeline Report
- DelveInsight’s Intrahepatic Cholangiocarcinoma Pipeline analysis depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Intrahepatic Cholangiocarcinoma treatment.
- The leading Intrahepatic Cholangiocarcinoma companies include Basilea Pharmaceutica, AstraZeneca, Delcath Systems Inc., Jiangsu HengRui Medicine Co., Ltd., Syndax Pharmaceuticals, Hutchison Medipharma Limited, Medivir, Newish Technology (Beijing) Co., Ltd., Relay Therapeutics, Inc., Exelixis, Forma Therapeutics, Inc., Xencor, Inc., Zymeworks, RedHill Biopharma Limited, Genoscience Pharma, Kinnate Biopharma, Taiho Oncology, Inc., Sirtex Medical, Virogin Biotech Ltd, TriSalus Life Sciences, Tyra Biosciences, Siranomics, Instylla, Inc., and others are evaluating their lead assets to improve the Intrahepatic Cholangiocarcinoma treatment landscape.
- Key Intrahepatic Cholangiocarcinoma pipeline therapies in various stages of development include Derazantinib, VG161, SD 101, FT-2102, KIN-3248, RLY-4008, TYR-200, HMPL-453, Opaganib, XmAb®22841, STP705, Camrelizumab, Embrace™ Hydrogel Embolic System, CTX-009, and others.
- In February 2022, HUTCHMED initiated a Phase Ib/II Study of HMPL-453 in Combination with Chemotherapy or Toripalimab for Advanced Solid Tumors, including intrahepatic cholangiocarcinoma in China. HMPL-453 is also being evaluated as monotherapy in Phase II clinical trials in China.
- In 2022, Basilea will continue its oncology activities to ensure project continuity and progression. For derazantinib, the company will continue the FIDES-01 study in intrahepatic cholangiocarcinoma (iCCA).
- In January 2022, US FDA cleared the Investigational New Drug (IND) application for KIN-3248 being developed by Kinnate Biopharma. KIN-3248 is a next-generation pan-FGFR inhibitor being developed for intrahepatic cholangiocarcinoma.
Request a sample and discover the recent breakthroughs happening in the Intrahepatic Cholangiocarcinoma pipeline landscape @ Intrahepatic Cholangiocarcinoma Pipeline Outlook
Intrahepatic Cholangiocarcinoma Overview
Intrahepatic Cholangiocarcinoma (ICC), also known as Intrahepatic Bile Duct Cancer, is a type of cancer that develops in the liver’s bile ducts. Intrahepatic Cholangiocarcinoma (ICC) is a relatively uncommon disease that accounts for approximately 10% of all cholangiocarcinomas. The 5-year survival rate for Intrahepatic Cholangiocarcinoma is 9%. The American Joint Committee on Cancer (AJCC) TNM staging method, which is now in its seventh edition and consists of four stages, is the most commonly used categorization system to evaluate the progression and resectability of Intrahepatic Cholangiocarcinoma. There was no separate Intrahepatic Cholangiocarcinoma staging method prior to this edition, and these tumors were classified as HCC.
Jaundice, abdominal pain, dark urine, clay-colored stool, fever, and itchy skin are the most common Intrahepatic Cholangiocarcinoma symptoms. Intrahepatic Cholangiocarcinoma is typically diagnosed when the tumor is unresectable due to locally advanced or metastatic disease. A liver mass, with or without biliary tract dilatation, is frequently detected using transabdominal ultrasound as the first imaging modality. Despite high recurrence rates of up to 80%, surgical excision is the only treatment option for Intrahepatic Cholangiocarcinoma. Intrahepatic recurrences may still be treated with curative intent in a small number of patients.
Find out more about Intrahepatic Cholangiocarcinoma medication @ New Drug for Intrahepatic Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma Pipeline Analysis: Drug Profile
Derazantinib: Basilea Pharmaceutica
Derazantinib is a small molecule inhibitor of the fibroblast growth factor receptor (FGFR) family of kinases that are taken orally. Derazantinib is currently being studied in phase II registrational study for intrahepatic cholangiocarcinoma (iCCA). Basilea released preliminary findings from this study in January 2019. The efficacy results were encouraging, and the analysis also confirmed derazantinib’s safety profile and tolerability observed in previous clinical studies.
Durvalumab is a human immunoglobulin G1 kappa (IgG1) monoclonal antibody that acts as a novel immune-checkpoint inhibitor in the treatment of cancer. Durvalumab, a programmed death-ligand 1 (PD-L1) blocking antibody produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, works to promote normal immune responses that attack tumor cells.
Intrahepatic Cholangiocarcinoma Pipeline Therapies and Key Companies
- Derazantinib: Basilea Pharmaceutica
- VG161: Virogin Biotech Ltd
- SD 101: TriSalus Life Sciences
- FT-2102: Forma Therapeutics, Inc.
- KIN-3248: Kinnate Biopharma
- RLY-4008: Relay Therapeutics
Learn more about the novel and emerging Intrahepatic Cholangiocarcinoma pipeline therapies @ Intrahepatic Cholangiocarcinoma Clinical Trials
Intrahepatic Cholangiocarcinoma Therapeutics Assessment
- By Product Type
- Combination Therapy
- By Stage
- Phase I
- Phase II
- Phase III
- By Route of Administration
- By Molecule Type
- Gene therapy
- Small molecule
- Monoclonal antibodies
Scope of the Intrahepatic Cholangiocarcinoma Pipeline Report
- Coverage: Global
- Key Intrahepatic Cholangiocarcinoma Companies: Basilea Pharmaceutica, AstraZeneca, Delcath Systems Inc., Jiangsu HengRui Medicine Co., Ltd., Syndax Pharmaceuticals, Hutchison Medipharma Limited, Medivir, Newish Technology (Beijing) Co., Ltd., Relay Therapeutics, Inc., Exelixis, Forma Therapeutics, Inc., Xencor, Inc., Zymeworks, RedHill Biopharma Limited, Genoscience Pharma, Kinnate Biopharma, Taiho Oncology, Inc., Sirtex Medical, Virogin Biotech Ltd, TriSalus Life Sciences, Tyra Biosciences, Siranomics, Instylla, Inc., and others.
- Key Intrahepatic Cholangiocarcinoma Pipeline Therapies: Derazantinib, VG161, SD 101, FT-2102, KIN-3248, RLY-4008, TYR-200, HMPL-453, Opaganib, XmAb®22841, STP705, Camrelizumab, Embrace™ Hydrogel Embolic System, CTX-009, and others.
Dive deep into rich insights for drugs used for Intrahepatic Cholangiocarcinoma treatment; visit @ Intrahepatic Cholangiocarcinoma Drugs
Table of Contents
|3.||Intrahepatic Cholangiocarcinoma Pipeline: Overview|
|4.||Analytical Perspective In-depth Commercial Assessment|
|5.||Intrahepatic Cholangiocarcinoma Pipeline Therapeutics|
|6.||Intrahepatic Cholangiocarcinoma Pipeline: Late Stage Products (Phase III)|
|7.||Intrahepatic Cholangiocarcinoma Pipeline: Late Stage Products (Phase III)|
|8.||Intrahepatic Cholangiocarcinoma Pipeline: Mid Stage Products (Phase II)|
|9.||Intrahepatic Cholangiocarcinoma Pipeline: Early Stage Products (Phase I)|
|12.||Company-University Collaborations (Licensing/Partnering) Analysis|
|16.||Market Drivers and Barriers|
|17.||Future Perspectives and Conclusion|
For further information on the Intrahepatic Cholangiocarcinoma therapy in the pipeline, reach out @ Intrahepatic Cholangiocarcinoma Medication
Intrahepatic Cholangiocarcinoma Market
Intrahepatic Cholangiocarcinoma Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Intrahepatic Cholangiocarcinoma companies involved such as Kinnate Biopharma, Taiho Oncology, Inc., Sirtex Medical, Virogin Biotech Ltd, TriSalus Life Sciences, among others.
Intrahepatic Cholangiocarcinoma Epidemiology Forecast
Intrahepatic Cholangiocarcinoma Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical and forecasted Intrahepatic Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Bile Duct Cancer Pipeline Insight, 2023 report provides comprehensive insights about the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the key Bile Duct Cancer companies involved, such as Merck, BMS, Elicio Therapeutics, among others.
Biliary Tract Cancers Pipeline
Biliary Tract Cancers Pipeline Insight, 2023 report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the key Biliary Tract Cancers companies involved, such as Merck, RemeGen, EMD Serono, SMT bio Co., Ltd., among others.
Progressive Familial Intrahepatic Cholestasis Pipeline
Progressive Familial Intrahepatic Cholestasis Pipeline Insight, 2023 report provides comprehensive insights about 2+ companies and 3+ pipeline drugs in the pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the key Progressive Familial Intrahepatic Cholestasis companies involved, such as Mirum Pharmaceuticals, Vivet Therapeutics, among others.
Biliary Atresia Pipeline Insight, 2023 report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in the pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the key Biliary Atresia companies involved, such as Mirum Pharmaceuticals, Albireo, Intercept Pharmaceuticals, among others.
Primary Biliary Cholangitis Pipeline
Primary Biliary Cholangitis Pipeline Insight, 2023 report provides comprehensive insights about 28+ companies and 28+ pipeline drugs in the pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the key Primary Biliary Cholangitis companies involved, such as Genfit, CymaBay Therapeutics, Mirum Pharmaceuticals, Gilead Sciences, among others.
Other Trending Reports
Goitre Market | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Global Kinase Inhibitor in Autoimmune Diseases Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market |Spirometers Market | Hemodynamic Monitoring Systems Market | Deep Brain Stimulation Devices Market | Genital Herpes Market | Guillain-Barre Syndrome (GBS) Market | Hot Flashes Market | Human Immunodeficiency Virus Type-1 (HIV-1) Market | Hypertrophic Scar Market | Sinus Dilation Devices Market | Artificial Cornea and Corneal Implant Market |Peripheral Neuritis Market | Peripheral Vascular Devices Market | Diphtheria Market | Glioma Market | Fallopian Tube Cancer Market | Implantable Cardioverter Defibrillators (ICDs) Market | Smart Inhalers Market | Thyroid Cancer Market | Hemostasis Market | Peptic Ulcers Market
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect With Us at LinkedIn | Facebook | Twitter